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Abstract
Background: Currently, two main technologies are used for screening of DNA copy number; the
BAC (Bacterial Artificial Chromosome) and the recently developed oligonucleotide-based CGH
(Chromosomal Comparative Genomic Hybridization) arrays which are capable of detecting small
genomic regions with amplification or deletion. The correlation as well as the discriminative power
of these platforms has never been compared statistically on a significant set of human patient
samples.
Results: In this paper, we present an exhaustive comparison between the two CGH platforms,
undertaken at two independent sites using the same batch of DNA from 19 advanced prostate
cancers. The comparison was performed directly on the raw data and a significant correlation was
found between the two platforms. The correlation was greatly improved when the data were
averaged over large chromosomic regions using a segmentation algorithm. In addition, this analysis
has enabled the development of a statistical model to discriminate BAC outliers that might indicate
microevents. These microevents were validated by the oligo platform results.
Conclusion: This article presents a genome-wide statistical validation of the oligo array platform
on a large set of patient samples and demonstrates statistically its superiority over the BAC
platform for the Identification of chromosomic events. Taking advantage of a large set of human
samples treated by the two technologies, a statistical model has been developed to show that the
BAC platform could also detect microevents.
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The study of the genomic imbalances in a variety of differ-
ent diseases, including cancer, is a major step towards the
understanding of disease development. In cancer cells, for
example, DNA copy number increases have been shown
to be one of the mechanisms by which oncogenes and
drug resistance genes can be activated, whereas loss of
DNA material may cause inactivation of tumor suppressor
genes. Knowledge of copy-number aberrations can have
also immediate clinical use in diagnosis and in some cases
can provide useful prognostic information. Association of
DNA copy-number aberrations with prognosis has been
found for a variety of tumor types, including prostate can-
cer [1], breast cancer [2], gastric cancer [3] and lymphoma
[4,5].
Chromosomal Comparative Genomic Hybridization
(CGH) is a molecular cytogenetic method for the detec-
tion of chromosomal imbalances and it has been exten-
sively used for studying copy number alterations in
various cancer types since it was first described in 1992 [6-
8]. As classical CGH has an average resolution of 10–20
megabases, it is able to detect changes affecting relatively
large chromosomal regions. The introduction of array-
based platforms has therefore greatly improved genomic
profiling and currently, two technologies are mainly used
for screening of DNA copy number; the BAC (Bacterial
Artificial Chromosome) and the oligonucleotide-based
CGH arrays. BAC-based CGH arrays were amongst the
first genomic arrays to be introduced [9] and are routinely
used to detect single copy changes in the genome, owing
to their high sensitivity. However, producing BAC clones
for array CGH (aCGH) is expensive and time-consuming
and, due to the large size of BACs, the limits of BAC aCGH
resolution have been reached. Oligonucleotide aCGH
[10,11] allow flexibility in probe design, greater coverage,
and much higher resolution. The latter depends on array
design and the cell type homogeneity. Moreover, oligonu-
cleotides can more easily be produced for any organism
for which the genome has been sequenced. Today, as
noted in [12], the aCGH field is evolving towards oligonu-
cleotide aCGH.
IJssel [13] has published a genome-wide validation of
their in-house spotted oligo aCGH using BAC arrays, for
human and mouse samples. These samples consist of one
human gastric tumour and two different mouse tumours,
and the comparison between BAC and oligo aCGH was
performed on the genomic profiles. In this study, IJssel
distinguished two kinds of noise, the technical noise and
the true genomic copy number polymorphisms [14]. Var-
ious algorithms for data denoising exist such as the non-
parametric method called circular binary segmentation
(CBS) [15] which splits the chromosomes into regions of
equal copy number. CBS is identified as one of the best
segmentation methods [16].
Here, we present a comprehensive comparison between
the two aCGH platforms using available data from 19
human advanced prostate cancer (European PRIMA
project, PRostate cancer Integral Management Approach)
obtained at two independent sites with the same batch of
DNA. This comprehensive comparison has been per-
formed on raw data sets and data analysed using CBS [15].
This represents the first genome-wide statistical validation
of the oligo array platform. In addition we have developed
a statistical method to identify BAC outliers that could
represent microevents.
Results
Probe distribution and noise levels for the BAC and oligo 
platforms
The repartitions of BACs and oligos on the human
genome were first compared. The uniformity of the 3040
BACs and the 40319 oligos repartition along the human
genome was tested using the Kolmogorov-Smirnov test
(p-value < 0.01), considering each chromosome arm as an
interval and each BAC and oligo as a point. BACs are uni-
formly distributed along all the chromosomes whereas
oligos are not, except on chromosome 18 and arms 7p,
10p and 19p.
Figure 1 illustrates the data from both platforms for the
same patient sample (819) along the human genome.
Both platforms detect aberrations, for instance on chro-
mosomes 8, 10 and 11, and the log-ratios of both plat-
forms oscillate around stable values. To measure the
noise, we have computed the autocorrelation of the log-
ratios inside each chromosome and found 0.36 and 0.18
for BAC and oligo aCGH data, respectively. This implies
that there is more baseline Variation in oligo-based aCGH
data compared to BAC aCGH data.
A log-ratio comparison of the oligo and BAC CGH 
platforms
The comparison was restricted to the 22 autosomes as the
available data were produced with the sex mismatch for
BAC aCGH and not for oligo aCGH. Each BAC value was
compared with the log-ratios of the corresponding oligos,
i.e oligos positioned between the start and the end of the
BAC. This comparison is not straight-forward as the mean
number of oligos per BAC across the 19 patients is only
2.5. The details of the distribution of the number of oligos
per BAC are shown in figure 2. A one-sample Student test
was performed for the 1345 BACs that overlap with at
least 10 oligos, so that the test had enough power. There
were 32 BAC log-ratios significantly different from their
corresponding oligo log-ratios (p-value < 0.01). To pro-
vide a more global comparison, a complementary analysisPage 2 of 10
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to at least one oligo in the 19 patients. The comparison
was done by Computing the Kendall correlation for all
pairs of BAC and oligo log-ratios, the oligo value being
a mean oligo log-ratio. The pair values are plotted on fig-
ure 3. The correlation gives a significant p-value inferior
to 1e - 15 with τ = 0.37. A τ value of 0.37 indicates that
both values of a pair increase or decrease with a proba-
bility of 68.5%. When the Kendall's correlation test is
performed excluding BACs containing fewer than 6 oli-
gos, τ reaches 0.44. This comparison shows that there is
a significant correlation between the BAC and the oligo
platform results.
Dotplot of BAC log-ratios versus oligo log-ratiosFigure 3
Dotplot of BAC log-ratios versus oligo log-ratios. The 
dot-plot has been done for the 43372 BACs of the 19 
patients having at least one corresponding oligo.
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Genomic data display for BAC and oligo aCGH dataFigure 1
Genomic data display for BAC and oligo aCGH data. The bottom plot represents BAC aCGH data on the human 
genome and the upper one the oligo aCGH data for the same patient sample (819). Red dotted-line on the two aCGH plots 
indicates two copies. The sex mismatch was performed for the BAC aCGH but not for the oligo.
Distribution of the number of oligos per BAC for all the 19 patient samplesFigure 2
Distribution of the number of oligos per BAC for all 
the 19 patient samples. 9975 BACs have no oligos and 
1345 have at least 10 oligos.
Nb of oligos per BAC
Nb
 o
f B
AC
s
0 5 10 15 20 25
0
50
00
10
00
0
15
00
0Page 3 of 10
(page number not for citation purposes)
BMC Genomics 2007, 8:84 http://www.biomedcentral.com/1471-2164/8/84Comparison between oligo and BAC CGH using 
segmentation
Oligo and BAC CGH platforms were compared after seg-
mentation into regions of equal copy number as the indi-
vidual number of copies can be corrupted with noise. The
Circular Binary Segmentation method (CBS) [15] was
used both for BAC and oligo data. This is illustrated in fig-
ure 4 for chromosome 3 from patient 817.
A statistical comparison was performed to assess the diver-
gence of the BAC and oligo data in the regions delimited
by the segmentation. Each segment is considered as a log-
ratios sample and two comparisons were made. Firstly, we
compared globally all the BAC and oligo Segments. Each
BAC segment was compared with the corresponding oli-
gos, located between the start and the end of the BAC seg-
ment. This was also done reciprocally with the oligo
Segments as the starting point, as the comparison is asym-
metrical. The pair segment mean values of all patient sam-
ples are shown in figure 5. The Kendall correlation gives a
p-value inferior to 1e - 15, with τ significantly greater
(0.81 and 0.80 for BAC and oligo Segments respectively)
than the value of 0.37 achieved without segmentation.
Secondly, all the segments were compared individually.
Before comparing the segment samples, a Shapiro test was
performed to determine whether their distributions are
gaussian. A Student test was used to compare the Gaussian
distributions, otherwise a Wilcoxon-Mann-Whitney test
was applied. A 1% false discovery rate [17] was then used
Chromosomic data display for BAC aCGH data and oligo aCGH dataFigure 4
Chromosomic data display for BAC aCGH data and oligo aCGH data. From bottom to top are represented on chro-
mosome 3 of patient sample 817, the BAC aCGH data plot, the oligo aCGH data plot, the segmented BAC data plot, the seg-
mented oligo data plot, the CGH BACs (in blue are represented the BAC outliers), the CGH oligonucleotides and the genes. 
The black dotted boxes indicate the different regions of detected BAC outliers (1, 2, 3, 4, 5 and 6).Page 4 of 10
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approaches we have identified 173 of 1231 (14%) BAC
segments with values divergent from oligo values (BAC
versus oligo) and 177 of 1560 (11%) oligo divergent seg-
ments (oligo versus BAC). To complete this result the
same comparison was done with a false discovery rate of
5% and 10%. For 5% the number of divergent segments
are then 272 and 338 for BAC versus oligo and oligo ver-
sus BAC respectively and for 10%, 299 and 375.
Finally, the comparison of the two platforms was focused
on the detection of aberrant events. We considered as
aberrations all segments with mean number of copies
lower than 1.5 or higher than 2.5. The BAC platform
detected 71 deletions and 74 amplifications among the 19
patient samples whereas the oligo platform detected 314
deletions and 209 amplifications with median lengths of
12 Mbp and 3.5 Mbp respectively. This shows that oligo
aCGH detect more, smaller chromosomal events than
BAC aCGH. Regarding the genomic location of these seg-
ments, 40 segments were found by both platforms either
deleted or amplified with an overlapping region compris-
ing more than 90% of each segment. It is important to
note that their median length is 27 Mbp, indicating that
large chromosomal aberrations are found by both plat-
forms.
In conclusion, segmentation enhances the correlation
between the two platforms. Another result is that the oligo
aCGH reveal many more, smaller aberrations.
Detection of outliers in BAC segments
In order to perform a more in-depth analysis of both plat-
forms, that could then be applied to the identification of
target genes and regions of genetic alteration, we devel-
oped a statistical model to detect BAC outliers and vali-
dated the results with the oligo CGH platform. An
advantage of the oligo CGH platform is its ability to detect
microevents. In this section we show that, to some extent,
the BAC aCGH platform, and more precisely BAC outliers
within segments, could indicate microevents.
BAC outliers can be detected by modelling their log-ratios
with a Gaussian distribution N(μs, σ) where μs is the the-
oretical mean of the BAC segment s and σ the Standard
deviation across all segments and all patients. However to
avoid misestimating σ by including too many outliers,
this parameter has been estimated on the least varying
patient, 812, containing n = 3017 BACs. Let s and  be
the estimators of μs and σ. To detect outliers the following
classical calculus was performed considering each BAC
value x inside its corresponding segment s of size ns. For
each BAC, μ was reestimated by Computing a new μs on
the ns - 1 value left after excluding the x value.
As  and  obey asymp-
totically the N(0, ) and N(0,1) law respectively,
the distribution of  is the N(0, ) law.
Besides, it is known that the law of  is asymptotically
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Global comparison between BAC and oligo SegmentsFigure 5
Global comparison between BAC and oligo Seg-
ments. The reference segments obtained by CBS [15] are 
BACs on the top plot and oligo on the bottom.
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obeys asymptotically a Student's law Tn-1. t is simplified to
: . A p-value is computed for
each BAC using the following procedure:
For each segment do
For each BAC inside current segment do
Produce a sample of all the segment log-ratios except
the current BAC one
Compute a p-value for the BAC value x according to
formula
Done
Done
All p-values are treated according to [17] taking FDR =
1%.
This model was used on the 19 patient samples. 990 out-
liers were detected in the genomic profiles of the patients,
across all the chromosomes. Figure 4 shows 4 isolated
BAC outliers (boxes 1, 2, 3 and 5) and two groups of BAC
outliers (boxes 4 and 6) on chromosome 3 of patient sam-
ple 817. Isolated BAC outliers point to putative micro-
events (microdeletion or small amplification) whereas
groups of BAC outliers may indicate larger aberred
regions. Finally to validate statistically this result, the Ken-
dall's correlation with oligos was computed for the 749
BAC outliers with at least one corresponding oligo giving
τ = 0.54 and a p-value of 1e - 15.
Discussion
The conceptual advantage of a high density oligo aCGH is
that it can reveal microdeletions or amplifications at the
gene level that may contribute to gene transcript Variation
and that are not detected on a BAC platform. Indeed the
oligo platform has an average 35 kbp spatial resolution
that enables to span all the well characterised genes
(defined in NCBI build 35, May 2004) providing suffi-
cient coverage for a genome wide survey of DNA aberra-
tions. Different sizes of microdeletions, from 2 to 7
probes have been detected by the CBS method, such as the
microdeletion containing the potential tumor suppressor
ATBF1 [18].
In this paper, oligo aCGH results are validated using the 3
k BAC aCGH platform on data from 19 patients. The clin-
ical material used in the PRIMA project is extremely unu-
sual, displaying greater than 75% tumour cellularity. In
general, other than in very advanced cancers, the level of
tumour cellularity would be significantly lower for pros-
tatic material and this together with lymphocytic infiltra-
tion might be expected to add to the noise component of
the oligo aCGH signal and reduce concordance both with
BAC array data and gene expression microarrays. The
number of patients involved in this experiment allowed
us to perform statistically significant analyses. Indeed
there are 1345 BACs that overlap with at least 10 oligos
and 43372 BACs with at least one oligo in the 19 patients.
The validation was first carried out directly, by matching
each BAC to the corresponding oligo raw data, and then
indirectly, using a segmentation algorithm called CBS
[15], which gave more significant results.
The Kendall's correlation on the raw data was significant,
with τ = 0.37, and was improved by segmentation, reach-
ing a value of 0.8. Correlation was therefore increased
more than two fold when compared to the direct compar-
ison, confirming the observation of IJssel [13], that BAC
and oligo profiles are very similar after smoothing. This
global analysis of all BAC and oligo Segments was com-
plemented by an individual comparison, where each seg-
ment from BAC or oligo platforms was tested against its
corresponding oligo or BAC data set. 14% and 11% of
BAC and oligo segments respectively were found to be
divergent. These percentages can be lowered (10% and
7%) by scaling the oligo values as the log-ratios are higher
for oligos than for BACs again in agreement with IJssel
[13] (figure 5). However these statistical tests only reveal
very divergent segments, indeed taking false discovery
rates equal to 5 or 10% gives higher percentages (22% and
19%, 27% and 22% respectively). So this number of
divergent segments should be regarded as a lower bound.
Indeed there were only few similar copy number aberra-
tions between the two platforms as the oligo platform pre-
sented the advantage to detect more, smaller
chromosomic aberrations. Secondly, we compared the
noise level between the two platforms on raw and seg-
mented data. Computing the autocorrelation along each
chromosome, we observed that the baseline variation for
BACs is lower than for oligos in agreement with previous
studies by IJssel [13] and Ylstra [12] who both computed
the standard deviation on regions without copy number
changes. Using the regions of equal copy numbers pro-
χn−12 t
n x
n
n
n
s s
s
=
− −
−
1
1
2
2
( )
( )
μ
σ
σ
σ
t
x n n
n n
s s
s
=
− − −
ˆ
ˆ
( )( )μ
σ
1 1
P T
x n n
n nn
s s
s
−
≥
− − −
⎛
⎝⎜⎜
⎞
⎠⎟⎟1
1 1ˆ
ˆ
( )( )μ
σPage 6 of 10
(page number not for citation purposes)
BMC Genomics 2007, 8:84 http://www.biomedcentral.com/1471-2164/8/84duced by CBS, the means of the oligo and BAC segments
standard deviations have been computed giving respec-
tively 0.32 and 0.10 confirming the previous result. BACs
with large insert clones display a lower variation com-
pared with the oligo platform. However, the trade-off is a
lower sensibility for BACs compared to oligos. Besides,
the standard deviation value of 0.32 of the oligo platform,
is small from a statistical point of view. Indeed, the confi-
dence interval of the true number of copies inside seg-
ments is small. For instance for a segment with 10 oligos
inside, a standard deviation of 0.32 means that for a mean
value of 3 copies, the interval is 2.5 – 3.6 (probability =
99%).
In spite of the many advantages of the oligo aCGH plat-
form, there is still some value in using the BAC platform.
BACs are distributed uniformly on the human genome so
that regions not previously found to be involved in cancer
or non-coding regions are covered. This terra incognita
may be interesting for further investigation, in particular
to search for microRNAs and repeated sequences. In addi-
tion, a BAC outlier detection model that could point to
putative microevents has been introduced in this article.
The BAC outlier values have been compared with the cor-
responding oligo values with good correlation. A large
number of these BAC outliers (35%) were found in
regions without known genes according to UCSC (June
2005). However these BAC outliers represent large regions
of 150 kbp and the potential microevents must still be
precisely located and biologically validated.
Conclusion
We have performed a large scale comparison of oligo and
BAC platforms using a set of 19 patient samples. First, we
have established statistically the reliability of the oligo
platform for the identification of chromosomic events.
Moreover the oligo platform outperforms the BAC tech-
nology for the detection of more, smaller aberrations.
Taking advantage of this large set of data, we have devel-
opped a statistical model, that highlights that BACs may
detect putative microevents. Hopefully, this result will
incite researchers to reconsider the potential use of BAC
data for more in-depth investigation of new data, as well
as for the numerous publically available BAC CGH data.
The challenge in future studies will be the routine estab-
lishment of banks of well-defined laser captured material,
so that the greater sensitivity of these platforms can be suc-
cessfully exploited. In order to obtain a more complete
picture of cancer, attempts could then be made to com-
bine the aCGH approaches with transcriptomic and pro-
teomic technologies.
Methods
Prostate cancer samples and DNA extraction
The analyzed sample set is composed of 19 advanced
prostate cancer samples from 18 patients. Frozen tissue
blocks were step-sectioned using a cryostat, and 20 μm
sections were collected in frozen tubes for subsequent
DNA and RNA extractions.
Isolation of DNA
DNA was extracted from the samples after overnight pro-
teinase K treatment using standard protocols [19]. For all
samples, the same batch of DNA was used for both BAC
and oligo aCGH analyses to make the data comparable.
BAC aCGH plateform
BAC clones were selected from RP-1, RP-5 and RP-6, RP-
11 [20] and CalTech BAC [21]. The clones were selected
from the published Golden Path and spaced at approxi-
mately 1-Mb intervals across the arm of each chromo-
some. Drosophila BACs were obtained from the RPCI-98
library [20]. All clones were screened for T1 phage con-
tamination, streaked to a single colony, and verified by
fingerprinting. Clone details can be obtained from the
Ensembl database accessed in the CytoView pages [22].
The resultant 1 Mb whole-genome BAC aCGH has been
previously described [19].
DNA was labeled by use of a Bioprime Labeling Kit (Inv-
itrogen, Carlsbad, CA) with modification of the nucleo-
tide mix. Briefly, a 84 μl reaction was set up containing
600 ng of DNA and a final concentration of 1 × Random
Primers Solution. After denaturing the DNA for 10 min at
100°C, 10 μl l0 × dNTP mix (0.5 mM dCTP, 2 mM dATP,
2 mM dGTP, 2 mMdTTP in TE-buffer), 4 μl 1 mM Cy5-
dCTP or Cy3-dCTP (NEN Life Science Products, Boston,
MA) and 2 μl Klenow fragment supplied in the kit were
added on ice to produce a final reaction volume of 100 μl.
The reaction was incubated at 37°C overnight and
stopped by adding 10 μl stop buffer (Bioprime Labeling
Kit; Invitrogen). Unincorporated nucleotides were
removed by use of microspin G50 columns (Pharmacia
Biotech, Piscataway, NJ) according to the instruction of
the suppliers.
The arrays have an area 3 × 2 cm. Female genomic DNA
was used as reference. Test and reference DNA (180 μl
each) were combined, precipitated together with 135 μl of
human Cot1 DNA (Invitrogen), and resuspended in 60 μl
of hybridization buffer (50% formamide, 10% dextran
sulfate, 0.1% Tween 20, 2 SSC, and 10 mM Tris/HCl, pH
7.4) and 3 μl of yeast tRNA (100 μg/μl; Invitrogen). A ring
of rubber cement was closely applied around the array to
form a well. After denaturing the sample for 10 min at
72°C, the denatured herring sperm Cot1 DNA mix was
added and the array incubated in a humidity chamberPage 7 of 10
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urated with 2 × SSC and 40% formamide on a table rock-
ing at 5 rpm at 37°C for 60 min. Arrays were
prehybridized as follows: 80 μl of herring sperm DNA (10
mg/ml; Sigma) and 135 μl of human Cot1 DNA (Invitro-
gen) were precipitated, resuspended in 80 μl of hybridiza-
tion buffer, and denatured for 10 min at 72°C. The
prehybridization solution was then removed and replaced
by the prehybridized genomic DNA. The slide was trans-
ferred into a small hybridization chamber containing
Whatmann 3 MM paper saturated with 2 × SSC and 20%
formamide, sealed with parafilm, and incubated on a
rocking table (5 rpm) at 37°C for 48 hr. Slides were
washed for 10 min at room temperature in PBS 0.05%
Tween 20, 30 min at 42°C in 50% formamide 2 × SSC,
and 10 min at room temperature in PBS 0.05% Tween 20,
before being dried by spinning in a centrifuge for 5 min at
150 g and stored until scanning.
Arrays were scanned by use of an Axon 4000B scanner
(Axon Instruments, Burlingame, CA). Images were ana-
lyzed by use of GenePix Pro 3.0 software (Axon Instru-
ments). Spots were defined by use of the automatic grid
feature of the software and manually adjusted where nec-
essary. Fluorescence intensities of all spots were then cal-
culated after subtraction of local background. To correct
for non-specific hybridization to spotted DNA, the mean
intensity of all of the Drosophila clones was subtracted for
each fluorochrome from each of the human clones before
ratio calculation (Drosophila correction).
Oligo aCGH platform
Oligonucleotide aCGH was performed according to the
protocol provided by Agilent Technologies (oligonucle-
otide aCGH for genomic DNA analysis, protocol version
2.0, August 2005, Agilent Technologies, Palo Alto, CA),
with minor modifications. Briefly, 12 μg of genomic DNA
was digested overnight with AluI and RsaI followed by
purification using phenol-chloroform extraction. Male
genomic DNA (catalog number G1471, Promega, Madi-
son, WI) was used as reference in all hybridizations in
order to analyse the chromosome X as its related copy
number alterations play a key role in prostate cancer. 3 μg
of digested tumour DNA and reference DNA was labeled
with Cy5-dUTP and Cy3-dUTP (PerkinElmer, Wellesley,
MA), respectively, in a random priming reaction using
Bioprime Array CGH Genomic Labeling Module (Invitro-
gen, Carlsbad, CA). After labeling tumor DNA and refer-
ence DNA samples were pooled, cleaned and
hybridization cocktails were prepared as instructed in the
protocol. Hybridization and washes were performed
according to the protocol using the human genome CGH
44B oligo microarrays (catalog number G4410-60520 by
Agilent Technologies). A laser confocal scanner (Agilent
Technologies) was used to obtain signal intensities from
targets, and Feature Extraction software (version 8.1.1.1,
Agilent Technologies) was applied in image analysis using
manufacturer's recommended settings
(44K_CGH_0605). To analyze the aCGH data we used
CGH Analytics software (version 3.2.32, Agilent Technol-
ogies). Quality metrics provided by CGH Analytics were
evaluated to ensure good data quality.
Array CGH data visualisation
The visualisation tool called CGHviewer was written in
Tcl/Tk. It was developed within the Gscope platform
(Ripp et al., in preparation). The program CGHviewer is
available as a Windows executable coupled with an
installer/uninstaller (Contact: carles@igbmc.u-strasbg.fr).
CGHviewer allows the import of text files. The human
genome annotation that has been integrated into the cur-
rent version of CGHviewer comes from the June 2005
assembly on the UCSC Genome Browser [23]. CGH-
viewer allows interactive graphical exploration of individ-
ual arrays or groups of arrays on genomic or chromosomic
scales. It also allows the detection and visualisation of the
BAC outliers. The visualisation of the aCGH data is pro-
vided before and after segmentation by CBS [15]. CGH
log-ratio values are all displayed as log2. For the genomic
displays, the plots consist of a x-axis divided into 24 chro-
mosomes (22 chromosomes plus chromosomes X and Y).
CGHviewer provides a zoom-in option and a view-finder.
Pointing at a measurement in a plot shows the coordi-
nates, and pointing at a box shows the "identity card" for
BAC clones, oligonucleotide probes, genes and cyto-
bands. The "identity card" includes information such as
the accession number, the human genome position and
for BACs and oligos, the log-ratio values.
Statistical methods
The autocorrelation for BACs and oligos has been com-
puted using the formula . The
autocorrelation measures the correlation in longitudinal
data between a position xi and the next position xi+1. In
this paper, xi and xi+1 correspond to consecutive BACs or
oligos. μ and σ are respectively the mean and the standard
deviation of the n log-ratios observed in a chromosome
either for BAC or oligo aCGH. The lower the autocorrela-
tion, the higher the noise.
Kendall's correlation is a ranks correlation measure
defined by τ = 2P((X1 - X2)(Y1 - Y2) > 0) - 1. In case of
independence between variables X and Y, τ follows the
gaussian law N(0, ) τ varies between -1 and 1,
and τ = 2P((X1 - X2)(Y1 - Y2) > 0) - 1 means that for two
( )( )x xi i
i
n − −+
=
−∑ μ μ
σ
1
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1
2 2 5
9 1
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( )
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smaller) than X1, then Y2 is greater (resp. smaller) than Y1
with a probability equal to P((X1 - X2)(Y1 - Y2) > 0).
The Circular Binary Segmentation method is a change
point analysis accessible through the DNAcopy, v1.1.2
(R) library [15]. The parameters were chosen as follows:
alpha = 0.01, number of permutations = 1000 and win-
dow size = 200 to increase the speed of the algorithm.
The R language was used for all statistical tests and plots
except for the detection of BAC outliers.
Abbreviations
BAC: Bacterial Artificial Chromosome; CGH: Chromo-
somal Comparative Genomic Hybridization; aCGH: array
CGH; CBS: Circular Binary Segmentation
Authors' contributions
The two first authors contributed equally to the work.
IGM, MW, AV, JAS, DEN and OK collected patient sam-
ples and designed the experiments. NW, AC, HE, FB and
BW analysed the data. NW and AC developed the statisti-
cal model and validated the BACs outliers. OP conceived
the study and participated in the analysis. All authors read
and approved the final manuscript.
Acknowledgements
The authors would like to thank all the members of the EU-FP6 PRIMA 
project (PRostate cancer Integral Management Approach) for useful discus-
sions and the European Union for financial support (PRIMA : LSHC-CT-
2004-504587), the Centre National de la Recherche Scientifique, the Uni-
versité Louis Pasteur, the Academy of Finland, the Finnish Cancer Organi-
zations and the Malaysian government. We are also grateful to Julie 
Thompson for critical reviewing and to Dr. Koichi Ichimura, Professor 
Peter Collins (Department of Pathology, University of Cambridge) for 
expert advice and technical support in undertaking the BAC-CGH array 
experiments.
References
1. Paris P, Andaya A, Fridlyand J, Jain A, Weinberg V, Kowbel D, Brebner
J, Simko J, Watson J, Volik S, Albertson D, Pinkel D, Alers J, van der
Kwast T, Vissers K, Schroder F, Wildhagen M, Febbo P, Chinnaiyan A,
Pienta K, Carroll P, Rubin M, Collins C, van Dekken H: Whole
genome scanning identifies genotypes associated with recur-
rence and metastasis in prostate tumors.  Hum Mol Genet 2004,
13:1303-1313.
2. Callagy G, Pharoah P, Chin S, Sangan T, Daigo Y, Jackson L, Caldas C:
Identification and validation of prognostic markers in breast
cancer with the complementary use of array-CGH and tissue
microarrays.  J Pathol 2005, 205:388-396.
3. Weiss M, Kuipers E, Postma C, Snijders A, Pinkel D, Meuwissen S,
Albertson D, Meijer G: Genomic alterations in primary gastric
adenocarcinomas correlate with clinicopathological charac-
teristics and survival.  Cell Oncol 2004, 26:307-317.
4. Martinez-Climent J, Alizadeh A, Segraves R, Blesa D, Rubio-Moscardo
F, Albertson D, Garcia-Conde J, Dyer M, Levy R, Pinkel D, Lossos I:
Transformation of follicular lymphoma to diffuse large cell
lymphoma is associated with a heterogeneous set of DNA
copy number and gene expression alterations.  Blood 2003,
101:3109-3117.
5. Rubio-Moscardo F, Climent J, Siebert R, Piris M, Martin-Subero J, Nie-
lander I, Garcia-Conde J, Dyer M, Terol M, Pinkel D, Martinez-Cli-
ment J: Mantle-cell lymphoma genotypes identified with CGH
to BAC microarrays define a leukemic subgroup of disease
and predict patient outcome.  Blood 2005, 105:4445-4454.
6. Kallioniemi A, Kallioniemi O, Sudar D, Rutovitz D, Gray J, Waldman
F, Pinkel D: Comparative genomic hybridization for molecu-
lar cytogenetic analysis of solid tumors.  Science 1992,
258:818-821.
7. Knuutila S, Björkqvist AM, Autio K, Tarkkanen M, Wolf M, Monni O,
Szymanska J, Larramendy M, Tapper J, Pere H, El-Rifai W, Hemmer S,
Wasenius VM, Vidgren V, Y YZ: DNA copy number amplifica-
tions in human neoplasms ? a review of comparative
genomic hybridization studies.  Am J Pathol 1998, 152:1107-1123.
8. Knuutila S, Autio K, Björkqvist AM, Aalto Y, El-Rifai W, Hemmer S,
Huhta T, Kettunen E, Kiuru-kuhlefelt S, Larramendy M, Lushnikova T,
Monni O, Pere H, Tapper J, Tarkkanen M, Varis A, Wasenius VM,
Wolf M, Zhu Y: DNA copy number losses in human neo-
plasms.  Am J Pathol 1999, 155:683-694.
9. Pinkel D, Segraves R, Sudar D, Clark S, Poole I, Kowbel D, Collins C,
Kuo W, Chen C, Zhai Y, Dairkee S, Ljung B, Gray J, Albertson D:
High resolution analysis of DNA copy number variation
using comparative genomic hybridization to microarrays.
Nat Genet 1998, 20:207-211.
10. Pollack J, Perou C, Alizadeh A, Eisen M, Pergamenschikov A, Williams
C, Jeffrey S, Botstein D: Genome-wide analysis of DNA copy-
number changes using cDNA microarrays.  Nat Genet 1999,
23:41-46.
11. Brennan C, Zhang Y, Leo C, Fenga B, Cauwels C, Aguirre A, Kim M,
Protopopov A, Chin L: High-resolution global profiling of
genomic alterations with long oligonucleotide microarray.
Cancer Res 2004, 64:4744-4748.
12. Ylstra B, van den Ijssel P, Carvalho B, Brakenhoff R, Meijer G: BAC
to the future! or oligonucleotides: a perspective for micro
array comparative genomic hybridization (array CGH).
Nucleic Acids Res 2006, 34:445-450.
13. van den IJssel PP, Chin MTS, Eijk P, Carvalho B, Hopmans E, Holstege
H, Bangarusamy D, Jonkers J, Meijer G, Caldas C, Ylstra B: Human
and mouse oligonucleotide-based array CGH.  Nucleic Acids Res
2005, 33:.
14. Sebat J, Lakshmi B, Troge J, Alexander J, Young J, Lundin P, Maner S,
Massa H, Walker M, Chi M, Navin N, Lucito R, Healy J, Hicks J, Ye K,
Reiner A, Gilliam T, Trask B, Patterson N, Zetterberg A, Wigler M:
Large-scale copy number polymorphism in the human
genome.  Science 2004, 305:525-528.
15. Olshen A, Venkatraman E, Lucito R, Wigler M: Circular binary seg-
mentation for the analysis of array-based DNA copy number
data.  Biostatistics 2004, 5:557-572.
16. Lai W, Johnson M, Kucherlapati R, Park P: Comparative analysis
of algorithms for identifying amplifications and deletions in
array CGH data.  Bioinformatics 2005, 21:3763-3770.
17. Benjamini Y, Hochberg Y: Controlling the False Discovery Rate:
A Practical and Powerful Approach to Multiple Testing.
J.R.S.S. Series B(Methodological) 1995, 57:289-300.
18. Sun X, Frierson H, Chen C, Li C, Ran Q, Otto K, Cantarel B, Vessella
R, Gao A, Petros J, Miura Y, Simons J, Dong J: Frequent somatic
mutations of the transcription factor ATBF1 in human pros-
tate cancer.  Nat Genet 2005, 37:407-412.
19. Fiegler H, Carr P, Douglas E, Burford D, Hunt S, Scott C, Smith J,
Vetrie D, Gorman P, Tomlinson I, Carter N: DNA microarrays for
comparative genomic hybridization based on DOP-PCR
amplification of BAC and PAC clones.  Genes Chromosomes Can-
cer 2003, 36:361-374.
20. BACPAC Resources Center   [http://bacpac.chori.org]
21. Caltech BAC Resource Center   [http://informa.bio.caltech.edu]
22. Hubbard T, Aken B, Beall K, Ballesterl B, Caccamo M, Chen Y, Clarke
L, Coates G, Cunningham F, Cutts T, Down T, Dyer S, Fitzgerald S,
Fernandez-Banet J, Graf S, Haider S, Hammond M, Herrero J, Holland
R, Howe K, Howe K, Johnson N, Kahari A, Keefe D, Kokocinski F,
Kulesha E, Lawson D, Longden I, Melsopp C, Megy K, Meidl P, Over-
duin B, Parker A, Prlic A, Rice S, Rios D, Schuster M, Sealy I, Severin
J, Slater G, Smedley D, Spudich G, Trevanion S, Vilella A, Vogel J,
White S, Wood M, Cox T, Curwen V, Durbin R, Fernandez-Suarez X,
Flicek P, Kasprzyk A, Proctor G, Searle S, Smith J, Ureta-Vidal A, Bir-
ney E: Ensembl 2007.  Nucleic Acids Res 2007.Page 9 of 10
(page number not for citation purposes)
BMC Genomics 2007, 8:84 http://www.biomedcentral.com/1471-2164/8/84Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
23. UCSC Genome Browser   [http://hgdownload.cse.ucsc.edu/gold
enPath]Page 10 of 10
(page number not for citation purposes)
